Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Primary Purpose
Chronic Stable Heart Failure
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
spironolactone + furosemide
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Stable Heart Failure focused on measuring heart failure, fibrosis, MMP, spironolactone, furosemide
Eligibility Criteria
Inclusion Criteria:
- chronic stable heart failure
Sites / Locations
Outcomes
Primary Outcome Measures
MMP levels
Secondary Outcome Measures
Full Information
NCT ID
NCT00663195
First Posted
April 18, 2008
Last Updated
April 18, 2008
Sponsor
Tottori University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00663195
Brief Title
Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Official Title
Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Tottori University Hospital
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Detailed Description
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Stable Heart Failure
Keywords
heart failure, fibrosis, MMP, spironolactone, furosemide
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
spironolactone + furosemide
Intervention Description
spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
Primary Outcome Measure Information:
Title
MMP levels
Time Frame
16 weeks
10. Eligibility
Sex
All
Eligibility Criteria
Inclusion Criteria:
chronic stable heart failure
12. IPD Sharing Statement
Learn more about this trial
Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
We'll reach out to this number within 24 hrs